Scoping review of studies evaluating frailty and its association with medication harm

A multimodal intervention to optimise antimicrobial use in residential aged care facilities (ENGAGEMENT): protocol for a stepped-wedge cluster randomised trial

Collaborative Optimisation and Ordering of Medications (COOM)

Evaluation of two European risk models for predicting medication harm in an Australian patient cohort

Validation and updating of the adverse inpatient medication event (AIME) model

The right time and place: the need for seven‐day pharmacist service models

Systematic review of machine learning models for personalised dosing of heparin

Evaluation of the Collaborative Ordering of Medications (COOM) pharmacist-physician model of care at the point of discharge in a digital hospital

Determining causality, severity and preventability of inpatient medication harm, including related hospital-acquired complications, using clinical coding data

Medicinal mishap: death from diltiazem-ibrutinib interaction

The pharmacist informatician: providing an innovative model of care during the COVID-19 crisis

Development and validation of the Adverse Inpatient Medication Event Model (AIME)

Prioritising patients at high-risk of medication harm: development and validation of risk prediction models

Vitamin D and the link with Parkinson’s disease: causal or correlational?

Identifying medication harm in hospitalised patients: a bimodal, targeted approach

How hospital pharmacists prioritise patients at high-risk for medication harm

Defining and classifying terminology for medication harm: a call for consensus

Prioritising hospital patients at high-risk of medication harm: development and validation of a predictive risk model

Reply to Iuga and Genaidy "Comment on Falconer et al. (2018) - the need for specific adverse drug reaction outcomes"

Systematic review of predictive risk models for adverse drug events in hospitalised patients